Measuring Disease Severity to Predict Patient Outcomes
Doctors need better diagnostics and biomarkers for disease severity to better treat patients and control epidemics.
We are developing a novel RNA test that quantifies immune system biomarkers to measure disease severity, predict patient outcomes early and provide potential therapeutic targets.
Cause vs. Effect
The World Health Organization’s position is that “better diagnostics and biomarkers predicting disease severity are urgently needed.”
While current diagnostics focus on the “cause” of disease (pathogen), we target the “effect” of disease (severity). The immune system is the missing link in understanding disease severity.
Decoding the Immune System's Signals
As the immune system is involved in virtually all diseases, decoding its signals enables revealing patient outcomes before they manifest clinically. Our proprietary immune system biomarkers allow the doctor to triage the patient and intervene medically at the earliest time point possible.
Discover how we can predict patient outcomes, regardless of disease.
Our first product will be a qPCR Screening Test for COVID-19 severity that enables doctors to make earlier triage and intervention decisions. Our second product will be an RNA-targeted Confirmation Test that provides doctors with a detailed expression analysis revealing the clinical stage of the patient’s disease. Both products are being developed on the basis of the data generated by our clinical trial.
These products are currently being tested and are not yet available.
How healthy or at-risk is the immune system of this patient?
How should I triage this patient: hospitalize or send home?
Which therapy or vaccine should I recommend to this patient now?
How has severity changed since I started treating this patient?